Tega Targets 3x Leverage as Molycop Integration Begins

Tega Industries Limited — Q4 FY26 Earnings Call (Quarter & FY ended Mar 31, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “strong visibility and confidence”, “healthy order pipeline”, and “robust growth”.
• Integration of Molycop is framed as “transformational milestone” with confidence in synergies and a clear deleveraging plan (“bring down the debt… to 3x of leverage”).

2. Key Themes from Management Commentary

• Strong FY26 performance with disciplined margins
• FY26 consolidated revenue: INR 17,736m (+5% YoY); EBITDA margin ~22%.
• Gross margins remain ~60%, attributed to operating discipline and resilient product mix.
• Order book strength / execution timing
• Order book: INR 12,060m; INR 9,060m executable within 12 months.
• Consumables revenue was flat due to timing shifts (orders booked late in Feb–Mar; execution expected in Q1–Q2).
• Equipment momentum
• Equipment revenue: INR 2,688m (+25% YoY); improved profitability (EBITDA margin 12%→13%, PBT margin 4%→8%).
• Molycop acquisition completed; integration + deleveraging focus
• Acquisition completed June 1, 2026; first consolidation expected end of June (Q1 FY27).
• Stated priorities: integration, synergies, and deleveraging (target 3x leverage in 3–4 years).
• Macro narrative used to support structural demand
• Gold demand: record levels; supply constrained.
• Copper demand growth vs constrained supply; long-term electrification tailwind.

3. Q&A Analysis

Theme A: Molycop consolidation mechanics + debt/capital structure

• Core questions
• When will consolidation happen?
• How much debt is added at parent level vs Molycop?
• Additional parent funding required?
• Management response
• Consolidation from June 1, first consolidation in end of June / Q1 results.
• Debt added: ~$838m in financials as of June 1 (with prior debt reduced from >$1,050m by ~$220m).
• Parent-level additional debt: INR 1,500 cr, already arranged (Standard Chartered + others) for acquisition financing/transaction expenses.
• Notable / evasive elements
• Guidance on total funding needs was answered in parts; the discussion clarified parent debt but did not fully reconcile the earlier “INR3,500 cr” framing from the analyst with the final stated debt/equity/cost components.

Theme B: Growth outlook for Tega vs Molycop (FY26/FY27)

• Core questions
• Expected growth for Tega and Molycop.
• Molycop FY26 revenue/margins and FY27 outlook.
• Management response
• Tega consumables: ~15% CAGR maintained.
• Equipment: ~25% growth (similar to FY26).
• Molycop: reassessing assumptions; FY27 growth guided at ~3% (to be refined).
• Molycop FY26 (year ending June 30): ~1% revenue growth, ~12% EBITDA margin (with caveat about consolidation alignment to March).
• Notable / unusually strong/weak answers
• The FY27 Molycop growth of ~3% is relatively conservative vs earlier market expectations; management attributed deferral of volume drivers to FY28 (care & maintenance mines not returning in FY27).

Theme C: Synergies + integration plan

• Core questions
• What synergies are expected and where (Tega vs Molycop)?
• How soon can synergy guidance be quantified?
• Management response
• Synergy “baskets”:
  • Revenue synergies in Tega
  • Cost synergies in Molycop
  • Sell non-core assets
• Uses 100-day / 200-day / line-wise plan; numbers are preliminary and will be guided later.
• Evasive element
• No quantified synergy value; explicitly “very preliminary” and deferred.

Theme D: Chile plant commissioning + revenue ramp timing

• Core questions
• Is Chile commissioning on track?
• How much revenue will be booked from Chile in FY27?
• Management response
• Civil work 50–60%; commissioning expected early Q3 (subject to regulatory approvals).
• Revenue booking: “hopeful” but could start end of Q4 or next year due to regulatory approvals.
• Evasive/partial
• Analyst asked for a clear FY27 revenue quarter; management gave a probabilistic answer (“hopeful”) rather than a firm booking schedule.

Theme E: Acquisition-related costs (timing/quantum)

• Core questions
• Has the full Molycop acquisition cost been booked?
• Will more costs hit Q1?
• Management response
• Some costs still to come; consultant/professional fees settle as work completes.
• Q1 expected higher quantum due to debt refinancing costs and preference costs crystallizing.
• Approximate “final payoff” acquisition costs: ~$30m in Q1.
• Notable
• Management corrected/clarified that earlier “loss” language was transaction expense, not operating loss.

Theme F: Consumables revenue flatness vs guidance; what changed

• Core questions
• Why consumables ended flat vs prior guidance (Feb call guided ~8%).
• Is it weak industry, market share loss, or execution/timing?
• Any longer-term revision to consumables growth?
• Management response
• Not market share loss; timing issue: orders shifted to end of Q3/Q4.
• Logistics disruption (Middle East disturbances) caused shipping/container constraints, increasing finished goods and pushing revenue recognition.
• Management reaffirmed 15%+ long-term and refused to revise down.
• Evasive/credibility risk
• They attribute the divergence to logistics and timing, but the pattern of “orders coming late” has recurred across quarters (see consistency section).

Theme G: Equipment margin guidance

• Core questions
• Why equipment had a “tale of two halves” (H1 strong, H2 flat).
• FY27 margin band.
• Management response
• Execution depends on site readiness/timeliness; quarter variability is normal; full-year guidance maintained.
• FY27 equipment EBITDA margin: 12%–13% (similar profitability to FY26).
• Notable
• Strong emphasis on lumpiness and “see over 1 year.”

Theme H: Working capital / DSO

• Core questions
• Why working capital improved; will it revert?
• Management response
• Improvement driven by payables and collections; DSO expected to remain 100–105 days.

4. Guidance / Outlook

Explicit guidance (quantitative)

• Tega consumables growth: “normal CAGR of about 15%” (going forward).
• Equipment growth: “range of 25%” for FY27 (similar to FY26).
• Blended EBITDA margin (Tega consolidated ex-Molycop synergies): management reiterated ~21%–22% blended.
• Chile capex (FY27): $25m–$30m (completion of Chile capex).
• Tega sustaining capex: INR 50–60 cr.
• Molycop capex (FY27): maintenance capex ~$20m (growth capex not yet factored).
• Molycop FY27 growth outlook: ~3% (to be refined after detailed engagement).
• Molycop FY26 (year ended Jun 30): ~1% revenue growth, ~12% EBITDA margin.

Implicit signals (qualitative)

• Consumables H1 FY27 expected to be “much better” due to executable order inflow and finished goods already produced.
• Chile revenue timing is uncertain: “hopeful” but may slip to end of Q4 / next year due to regulatory approvals.
• Synergy quantification deferred until integration plans mature (100/200-day).

5. Standout Statements (direct / revealing)

• Order visibility: “order book stands at approximately INR12,060 million with INR9,060 million executable within the next 12 months.”
• Integration priority: “successful integration… across key functions… unified operating standards and robust governance.”
• Deleveraging target: “bring down the debt… to a level wherein 3x of leverage” (3–4 years).
• Consumables explanation: revenue flatness is “a timing issue” and orders shifted to “February and March.”
• Logistics disruption admission: “logistical challenge… vessel connectivity… container availability… increase in finished goods.”
• Molycop conservatism: FY27 growth “is 3%” and volume jump deferred: “deferred to FY ’28.”
• Acquisition cost timing: “quantum will be much higher… anticipate a higher number in Q1… close to $30 million.”
• Chile revenue uncertainty: “we are hopeful… but it may be… start booking from end of Q4 or maybe next year.”

6. Red Flags / Positive Signals

Red flags
– Recurring “timing/spillover” narrative for consumables revenue (flat FY26; Q4 execution lag explained by logistics/order timing).
– Molycop outlook reset to conservative FY27 growth (~3%) with volume drivers deferred to FY28—suggests earlier assumptions may have been optimistic.
– Synergy guidance remains non-quantified despite being central to the acquisition story.
– Chile revenue timing remains uncertain (regulatory approvals), reducing confidence in near-term earnings contribution.

Positive signals
– Strong order book and executable backlog (INR 9,060m within 12 months).
– Gross margin resilience (~60%) despite volatility.
– Working capital discipline: DSO guidance maintained at 100–105 days.
– Clear capex funding plan (internal accruals + existing borrowing; Molycop capex framed as manageable from cash flows).

7. Historical Comparison & Consistency Analysis

a. Change in Tone Over Time

• Current call (Jun 2026): More Optimistic
• Stronger emphasis on completed acquisition (“transformational milestone”) and confidence from order book visibility.
• Prior calls (Nov 2025, Feb 2026): Neutral to Optimistic
• Feb 2026 explicitly said “cautiously optimistic.”
• What changed
• Management moved from pre-close regulatory/financing uncertainty (Nov/Feb) to post-close execution/integration.
• However, Molycop growth expectations became more conservative (FY27 ~3%) vs earlier implied upside narratives.

b. Tracking Past Commitments vs Outcomes

• Chile commissioning timing
• Past statement (Nov 13, 2025): “ready for commercial production by Q2 FY27” and earlier “September ’26” references.
• Current call: commissioning early Q3; revenue booking could be end of Q4 or next year.
• Status: ⏳ Delayed / timing risk increased (commercial booking now less certain).
• Molycop closing timeline
• Past (Nov 13, 2025): expected close “end December / January” (and first consolidation in Q4 FY26).
• Current: acquisition closed June 1, 2026; first consolidation Q1 FY27.
• Status: ❌ Delayed (material slip vs prior expectation).
• Consumables growth guidance
• Past (Feb 12, 2026): management guided consumables to be high single-digit and long-term 15% CAGR; also expected Q4 strength.
• Current: consumables FY26 ended flat; explanation again timing/logistics.
• Status: ⏳ Not delivered on near-term trajectory (but long-term CAGR reaffirmed).

c. Narrative Shifts

• From “macro uncertainty but confident” → “execution timing + logistics constraints”
• The consumables story has increasingly relied on shipping/container disruptions and order-to-revenue timing.
• Molycop story shifted
• Earlier calls focused on regulatory approvals and deal progress; now the narrative includes deleveraging, synergy planning, and lower FY27 growth with volume deferral to FY28.
• Chile contribution narrative weakened
• From “on track” to “hopeful” revenue booking with regulatory dependency.

d. Consistency & Credibility Signals

• Credibility: Medium
• Strength: consistent margin framing (gross ~60%, blended EBITDA ~21–22%).
• Weakness: timeline credibility has slipped (Molycop close, Chile revenue certainty), and near-term consumables execution continues to disappoint vs earlier implied strength.
• Management often uses “timing/spillover” explanations; while plausible, the recurrence reduces confidence.

e. Evolution of Key Themes

• Demand/macro: remains supportive (gold/copper structural demand), no major deterioration.
• Margins: gross margin resilience maintained; EBITDA margin slightly pressured by mix/timing and acquisition/labor code items.
• Expansion/investment: capex plan continues, but Chile ramp timing risk is now more explicit.
• Integration/synergies: moved from deal completion to planning, but quantification deferred.

f. Additional Insights (Cross-Period Intelligence)

• The company’s repeated reliance on late-quarter order booking and logistics disruptions suggests a structural vulnerability: revenue recognition is sensitive to shipping/dispatch constraints, not just demand.
• The Molycop FY27 growth reset to ~3% plus deferral of volume recovery to FY28 implies that some earlier “volume rebound” assumptions (care & maintenance mines returning) are not materializing on the expected timeline.
• Acquisition costs are still flowing into Q1 (refinancing/preference costs), meaning reported earnings volatility may persist into FY27 even if operating performance stabilizes.